早期应用强心甙与血管活性药物对重症肺炎并心衰预后的评估  

Effect of early use of cardenolides and vasoactive agents on prognosis of severe pneumonia complicated by heart failure

作　　者：李波 

机构地区：[1]云南省楚雄州人民医院,云南楚雄675000

出　　处：《心血管病防治知识（学术版）》2015年第7期85-87,共3页Prevention and Treatment of Cardiovascular Disease

摘　　要：目的探讨早期应用强心甙与血管活性药物对重症肺炎并心衰预后情况的影响。方法选取2011年11月至2014年11月我院收治的重症肺炎并心衰患儿50例,采用随机分组方法分为两个小组,对照组患儿25例,主要进行传统药物治疗,观察组患儿25例,主要在早期进行强心甙与血管活性药物治疗,对比两组患儿后期治疗结果。结果经过观察分析,在患儿治疗有效率上,观察组明显高于对照组,在患儿后期症状改善情况上,观察组明显优于对照组,在患儿住院时间上,观察组明显短于对照组。结论在重症肺炎并心衰患儿临床治疗当中,早期应用强心甙与血管活性药物治疗效果较好,不仅可以有效改善患儿临床症状,且可以明显改善患儿预后情况,效果显著。Objective To investigate the effect of early use of cardenolides and vasoactive agents on the prognosis of severe pneumonia complicated by heart failure. Methods A total of 50 children with severe pneumonia complicated by heart failure treated in our hospital between November 2011 and November 2014 were selected, and randomly divided into control group and observation group, with 25 patients in each group. The control group was treated with traditional drugs, while the observation group was treated with cardenolides and vasoactive agents in the early period. The treatment outcomes in the later period were compared between the patients of the two groups. Results After observation and analysis, the observation group had a significantly higher response rate, a significantly more improvement in symptoms in the later period, and a significantly shorter length of stay, as compared with the control group. Conclusion When treating children with severe pneumonia complicated by heart failure, early use of cardenolides and vasoactive agents has good efficacy, and can not only effectively improve the clinical symptoms, but also significantly imnrove the nrognosis of children.

关 键 词：早期应用 强心甙 血管活性药物 重症肺炎并心衰 预后 

分 类 号：R725[医药卫生—儿科]